Teva’s thrice-weekly Copaxone is priced at about a 10% discount to regular (daily) Copaxone, according to MNTA’s CFO, Rick Shea on today's Leerink webcast. (This differs from the prior unconfirmed report that the discount was 2%.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”